ONWARD: Oral Envudeucitinib Demonstrates High PASI Responses in Phase 3, With Andrew Blauvelt, MD

Phase 3 data for envudeucitinib — a next-generation, highly selective oral TYK2 inhibitor precision-engineered for maximal 24-hour target inhibition — have demonstrated robust skin clearance in moderate-to-severe plaque psoriasis (PsO), in new data presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 held in Denver, Colorado, from March 27-31.

To discuss the findings, we spoke with Andrew Blauvelt, MD, MBA, Owner of Blauvelt Consulting, LLC, in Annapolis, Maryland, and a principal investigator on the ONWARD program, following his late-breaking oral presentation at the meeting. The ONWARD1 and ONWARD2 trials together enrolled more than 1,700 adults with moderate-to-severe plaque psoriasis, randomized 2:1:1 to envudeucitinib 40 mg twice daily, placebo, or the active comparator apremilast, with co-primary endpoints of PASI 75 and static Physician's Global Assessment (sPGA) 0/1 at week 16. Both studies met all primary and secondary endpoints with high statistical significance versus placebo (

At week 16, approximately 74–75% of envudeucitinib-treated patients achieved PASI 75 and 59% achieved sPGA 0/1 — substantially higher than both placebo and apremilast. Blauvelt highlighted the week 24 data as particularly noteworthy: consistent with the class behavior of TYK2 inhibitors, response deepened over time, with approximately 80% achieving PASI 75, approximately 65% achieving PASI 90, and more than 40% achieving PASI 100 — complete clearance — by week 24. Envudeucitinib outperformed apremilast on all PASI endpoints at week 24 (

 <.0001), and separation from placebo on PASI 90 was observed as early as week 4. Patient-reported quality-of-life and itch measures were consistent and clinically meaningful throughout. 

On safety, the profile was favorable and consistent with phase 2 findings — the most common adverse events were nasopharyngitis and upper respiratory tract infection, with no major cardiovascular events, no tuberculosis reactivation, no clinically relevant hematologic or metabolic laboratory abnormalities, and notably no lipid signal of the kind observed in earlier deucravacitinib studies. 

Blauvelt distinguished envudeucitinib from deucravacitinib as a second-generation TYK2 inhibitor specifically engineered for complete 24-hour target coverage — the only TYK2 inhibitor shown to achieve maximal inhibition over a full dosing interval in humans. An NDA submission is planned for the second half of 2026, with a once-daily extended-release formulation and a pediatric program both in development.

“[This was] a major reveal… phase 3 results for a new oral drug for psoriasis called envudeucitinib, next gen TYK2 inhibitor. If all goes well, if the FDA likes it… usually when phase 3 results are presented at AAD, oftentimes, we will see approval of the drug in the coming year,” Blauvelt said.

Blauvelt’s disclosures include Abbvie, Almirall, Alumis, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis Biotherapeutics, Eli Lilly, Incyte, Janssen, LEO Pharma, Lipidio Pharma, Novartis, Oruka Therapeutics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, Takeda, and UCB.

Blauvelt A, Sofen H, Armstrong A, et al. Envudeucitinib (ESK-001) in Moderate-to-Severe Plaque Psoriasis: 24-Week Results From the Randomized, Double-Blind, Active Comparator- and PlaceboControlled, Phase 3 ONWARD1 and 2 Studies. Presented at: AAD Annual Meeting; Denver, Colorado; March 27-31. 

Alumis Inc. Alumis' envudeucitinib delivers early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two phase 3 trials, underscoring its potential as a leading oral therapy for plaque psoriasis. Press release. March 28, 2026. 

https://investors.alumis.com/news-releases/news-release-details/alumis-envudeucitinib-delivers-early-and-robust-improvements

Videos

Blauvelt discussed highlights from the phase 3 ONWARD1 and ONWARD2 clinical trials presented at AAD 2026.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Cheng Zhou, MD, is a professor and chair of the department of dermatology at Peking University People`s Hospital in China.

Rademikibart treatment of adults and adolescents living with 

 leads to rapid and clinically significant improvements, new data suggest, with many improvements sustaining through 52 weeks.

These data were the result of a phase 3 study of rademikibart presented in the late-breaking research session at the 

 in Denver, Colorado. To discuss the findings in depth, as well as their significance, the 

 team spoke in a Q&A interview with Cheng Zhou, MD, of Peking University People’s Hospital.

Zhou, an investigator in the RADIANT-AD trial from which these data were drawn, spoke about these results in detail. His written responses are transcribed here:

HCPLive: Can you walk us through the top-line results from the phase 3 trial — what did rademikibart actually show?

The phase 3 RADIANT‑AD trial showed that rademikibart produced rapid, clinically meaningful improvements in adults and adolescents with moderate‑to‑severe atopic dermatitis, with responses that continued to deepen and were sustained through 52 weeks.

At Week 16, rademikibart significantly outperformed placebo across all major efficacy endpoints, and importantly, patients continued to improve over time rather than reaching an early plateau. By one year, a large majority of patients achieved near‑maximal skin clearance and sustained itch control, supporting both the durability and consistency of response.

What were the primary endpoints, and were they met?

 The study had two co‑primary endpoints: the proportion of patients achieving an Investigator’s Global Assessment score of 0 or 1 with at least a 2‑point reduction, and the proportion achieving at least a 75% improvement in EASI score at Week 16. Both endpoints were met with strong statistical significance.

At Week 16, 47.4% of patients treated with rademikibart achieved IGA 0/1, compared with 17.6% on placebo, while 74.2% achieved EASI‑75 versus 34.4% with placebo (both p<0.001). Importantly, these responses continued to improve over time, with IGA 0/1 and EASI‑75 rates rising to 87.1% and 96.6%, respectively, by Week 52, underscoring the durability of the treatment effect.

How did the drug perform on itch and quality of life measures, not just skin clearance?

 Rademikibart demonstrated rapid and sustained improvement in itch, a major driver of quality of life in atopic dermatitis. By Week 16, 54.7% of patients treated with rademikibart achieved a clinically meaningful ≥3‑point reduction in pruritus score, compared with 27.5% on placebo (p<0.0001), with responses continuing to deepen over time; by Week 52, 91.2% of patients achieved this level of itch improvement. Importantly, clinicians often view a ≥4‑point reduction as an even more stringent and clinically meaningful benchmark, and analyses using this higher threshold showed a similar pattern of robust and durable separation from placebo.

While broader quality‑of‑life and other patient‑reported outcome measures have not yet been fully reported and will be presented separately, the magnitude and durability of itch reduction observed are strongly aligned with meaningful day‑to‑day functional benefit for patients.

: What did the safety profile look like, and were there any findings that stood out to you?

: Overall, rademikibart demonstrated a safety profile comparable to placebo through Week 16 and consistent with long‑term IL‑4/IL‑13 pathway inhibition through Week 52. Rates of serious adverse events, treatment discontinuations, and injection‑site reactions were low, and no new safety signals emerged over one year of treatment. One finding of particular interest was the low and placebo‑comparable rate of conjunctivitis (3.9% vs 3.1%), which is a known concern for dermatologists using existing therapies in this class.

Were there any side effects that clinicians should be aware of when thinking about this drug?

: The side effects observed with rademikibart were generally consistent with what clinicians would expect for biologic therapies targeting type 2 inflammation, with most events being mild to moderate in severity. Conjunctivitis occurred at low rates and was comparable to placebo, and treatment‑related discontinuations were rare. As with any systemic biologic therapy, clinicians should remain attentive to overall tolerability and routine safety monitoring, but no unexpected or treatment‑limiting adverse effects were identified in this trial.

What questions does this trial leave unanswered, and what would you want to see studied next?

: While the phase 3 RADIANT‑AD trial clearly establishes strong and rapid efficacy and one‑year durability, important questions remain regarding the broader patient experience and longer‑term use. Ongoing and planned analyses of patient‑reported outcomes and quality‑of‑life measures will help further contextualize the depth and clinical relevance of the benefits observed with rademikibart. In addition, longer follow‑up beyond one year will be important to better characterize the impressive durability of response and long‑term safety, as well as to understand how these results translate across the diverse patient subgroups encountered in real‑world dermatology practice.

What is the timeline toward a potential FDA submission?

: At this time, neither Connect Biopharma nor its partner Simcere has publicly disclosed a specific timeline for an FDA submission in atopic dermatitis. The current RADIANT AD study was conducted by Simcere in China and the results create options outside of China for an active US regulatory filing plan. Any submission would follow completion of full analyses and internal strategic review, but no timing has been announced.

Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. Connect Biopharma Holdings Limited. March 10, 2026. Accessed March 31, 2026. 

https://investors.connectbiopharma.com/news-releases/news-release-details/results-phase-3-study-rademikibart-moderate-severe-atopic

Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from phase 3 REMIX-1/-2 studies. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Articles

Phase 3 data on rademikibart in moderate-to-severe atopic dermatitis (AD) have been released from the AAD late-Breaking research session.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

RADIANT-AD: Rademikibart Effective Over 52 Weeks in Atopic Dermatitis, With Cheng Zhou, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Remibrutinib treatment of chronic spontaneous urticaria (CSU) leads to fast, early symptom control versus placebo, according to new post-hoc analysis data presented at the 

CSU is a chronic, idiopathic condition characterized by the recurrence of hives, pruritus, angioedema, or a combination of such symptoms lasting longer than 6 weeks.

 The condition is known to disproportionately impact women, and this is especially the case among those between 20 - 40 years of age. CSU is linked with a substantial burden, as beyond its physical manifestations, the disease has significant psychological and economic implications. The annual healthcare-related costs of CSU in the US exceed $200 million.

Remibrutinib is an oral, highly selective Bruton's tyrosine kinase (BTK) inhibitor, and had previously demonstrated efficacy and a positive safety profile in previous phase 2b data.

 During the latest phase 3 REMIX-1 and REMIX-2 trials, which are identical, multicenter, randomized, double-blind, placebo-controlled studies, remibrutinib was administered as an add-on therapy for patients whose symptoms persisted despite second-generation H1-antihistamines.

In these new data, the drug showed superior efficacy compared with placebo at the 12-week mark. The therapy has since been approved in both the US and China. In the current post-hoc analysis pooled data from the REMIX-1 and REMIX-2 trials, presented during AAD 2026, the investigative team set out to better understand how quickly patients begin to experience CSU symptom improvement after beginning remibrutinib treatment.

The team focused on daily hive severity scores (HSS) and itch severity scores (ISS), seeking to assess both mean shifts in scores over time and the proportion of individuals in the studies attaining complete resolution of their CSU symptoms (defined as HSS = 0 for no hives and ISS = 0 for no itch) from baseline through the first 7 days of therapy use.

They calculated both HSS and ISS via averaged morning and evening assessments, with the exception of the first day. This was when only the post-dose evening measurement, taken 12 hours after dosing, was included due to pre-dose morning values. Scoring of CSU severity ranged from 0 - 3, with higher scores suggesting a greater level of symptom burden.

Overall, the investigators’ pooled post-hoc data showed remibrutinib implementation led to a rapid reduction in CSU disease activity, with the investigators noting measurable improvements in both itch and hive severity within the first 12 hours following the initial remibrutinib dose. This early onset of action was notably faster than what was observed in the placebo arm. Additionally, the team found a higher proportion of those on remibrutinib attained complete resolution of symptoms within this same 12-hour timeframe.

The benefits persisted over the initial week of treatment. Across days 1 - 7, participants treated with remibrutinib consistently showed greater rates of complete CSU symptom control compared with subjects in the placebo arm. The proportion of those reaching HSS = 0 and ISS = 0 remained higher in the treatment cohort throughout this early treatment period.

Safety results from the pooled analysis were also described as consistent with previous reports from the REMIX program. Remibrutinib was generally well-tolerated, with a lack of new safety concerns being identified.

Overall, these data reinforce earlier findings from the phase 3 research, highlighting not only the efficacy and safety of remibrutinib but also its rapid onset of action. The drug’s ability to attain early symptom control may be particularly meaningful for those with CSU who continue to experience significant burden despite standard antihistamine use.

Early symptom improvement with remibrutinib in chronic spontaneous urticaria: Daily Itch Severity Scores and Hives Severity Scores from phase 3 REMIX-1/-2 studies. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO. Poster DV-018384.

Metz M, Giménez-Arnau A, Maurer M, et al. Remibrutinib in Chronic Spontaneous Urticaria. N Engl J Med. 2025 Mar 6;392(10):984-994. doi: 10.1056/NEJMoa2408792. PMID: 40043237.

Tbakhi B, Ware K, Bernstein JA, et al. An Overview of Chronic Spontaneous Urticaria: Diagnosis, Management, and Treatment. Allergy Asthma Immunol Res. 2025 Sep;17(5):531-546. doi: 10.4168/aair.2025.17.5.531. PMID: 41044830; PMCID: PMC12511800.

These data from REMIX-1 and 2 suggest remibrutinib, in those with chronic spontaneous urticaria (CSU), can lead to fast, early symptom control.

Urticaria

The HCPLive urticaria page is a comprehensive resource for clinical news and insights on chronic idiopathic urticaria and chronic spontaneous urticaria. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for urticaria, and more.

REMIX: Early CSU Symptom Improvement Observed with Remibrutinib Therapy

Monica Kraft, MD, is Murray M. Rosenberg Professor of Medicine and System Chair for the Department of Medicine at Mount Sinai Health System and the Icahn School of Medicine at Mount Sinai.

AI-Enhanced ECGs Detect Early COPD, With Monica Kraft, MD

Recent research suggests that routine electrocardiograms (ECGs) analyzed through artificial intelligence (AI) may offer a scalable approach to identifying early 

, Monica Kraft, MD, of the Icahn School of Medicine at Mount Sinai, discussed key findings from a new study that assessed the accuracy of an automated COPD diagnosis using deep learning on ECGs.

“A lot of patients, especially as the years go by, undergo cardiology evaluation and don't necessarily have the lungs evaluated similarly,” Kraft said. “[This tool] may allow us to bring other issues to light.”

Chronic obstructive pulmonary disease (COPD) remains a leading cause of morbidity and mortality worldwide. The non-specific symptoms and reliance on time- and resource-intensive testing often delay a diagnosis.

Kraft and colleagues analyzed ≥ 760,000 ECGs across multiple hospital systems and the UK Biobank using a convolutional neural network, demonstrating robust performance in detecting COPD (area under the curve, 0.80–0.82). Kraft emphasized the role of subtle P wave changes as early indicators of COPD.

“The lungs and the heart are very interrelated,” she explained. “The heart is very subject to pressure changes that go on in the lung. COPD starts in [the] smallest [lung branches]. They can be a millimeter in size. The air that we breathe can get into those little airways, but has trouble getting out because those small airways are closed off. And so, those little airways don't empty as well. They hold on to this air, and the lungs get a little bit bigger than they should. That size change…can be very subtle, [and] early on, alters the pressure between the lungs and the heart and also the lungs and the ribs, the chest wall and the diaphragm, all these relationships get altered. Those…subtle pressure changes, we think, actually have an impact on the P wave.”

The model performed well in patients with documented smoking histories, underscoring its relevance to populations at greater risk. Kraft noted potential future applications for other obstructive airway diseases, such as asthma, cystic fibrosis, and bronchiectasis, although further study is needed.

If applied across a health system, Kraft said the algorithm could flag possible COPD on routine ECGs. Cardiologists could note this, prompting primary care providers to initiate further evaluation or pulmonology referral. This could lead to earlier intervention and improved outcomes.

She cautioned that the model is not perfectly specific. Only about 70% of flagged ECGs corresponded to confirmed COPD. Kraft said that a prospective evaluation will be important to define disease severity and guide clinical response before widespread deployment.

Despite limitations, Kraft highlighted the promise of AI-enhanced ECGs, which are inexpensive and easily accessible. Early detection of COPD could slow lung function decline, reduce hospitalizations, and improve survival. This study supports AI-based ECG as a tool for early COPD recognition, complementing traditional diagnostic methods such as spirometry.

“We need to remember that we also are at the early stages of this approach,” Kraft said. “We can identify COPD early, but we need to now understand what is the extent of the disease that we're identifying. We know a little bit about that from the chart review, but what we want to do is bring those patients in live and do an evaluation so that we can describe the type of COPD that we are identifying. Those are all pieces that are in the works…before it becomes a decision support tool at the ECG level, we would need to sort all of that out.”

Part 1 of our interview with Kraft can be viewed 

A relevant disclosure for Kraft includes AstraZeneca Pharmaceuticals LP.

Vaid A, Sharma J, Jiang J, et al. Automated diagnosis of chronic obstructive pulmonary disease using deep learning applied to electrocardiograms. 

Deep learning applied to routine ECGs identifies subtle cardiac signals linked to early COPD, potentially enabling earlier diagnosis and intervention.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

VELA: Phase 3 Data Suggest Sonelokimab Effective for HS, With Alexa Kimball, MD, MPH

 suggest sonelokimab may deliver sustained clinical and quality-of-life improvements for adults with moderate-to-severe hidradenitis suppurativa (HS).

These findings resulted from the phase 3 VELA-1 and VELA-2 trials. In an on-site interview, VELA trial investigator Alexa Kimball, MD, MPH, of Harvard Medical School, discussed the broader implications of these findings, including how higher response thresholds like Hidradenitis Suppurativa Clinical Response (HiSCR) 75 may help redefine treatment goals and expectations in HS management.

“What was great to see in the data…is that the efficacy seems to be quite have a very high slope at the beginning of treatment and then continues to improve over time through Week 40 with hidradenitis suppurativa,” Kimball expressed.

838 individuals were assessed in the global VELA program, with investigators utilizing the more stringent HiSCR 75 as their primary endpoint, reflecting at least a 75% reduction in patients’ abscess and inflammatory nodule count without worsening of abscesses or draining tunnels. Kimball et al found, by Week 40, approximately 62% of those on sonelokimab attained HiSCR75, with up to 32% achieving complete lesion clearance (HiSCR100).

These findings were described as consistent across both analyses, suggesting a high level of durable disease control with the drug’s use. Additional measures of HS severity and symptom burden also demonstrated meaningful improvement, Kimball and colleagues found. Up to 77% of those evaluated achieved at least a 55% reduction in International HS Severity Scoring System (IHS4-55), and approximately a quarter reached inflammatory remission. Such outcomes point to substantial reductions in inflammatory activity.

Notably, Kimball and coauthors’ clinical gains were accompanied by notable improvements in the patient-reported outcomes seen in the VELA program. Quality-of-life scores, as determined by the HS Quality of Life (HiSQOL) instrument, were found to have risen significantly through the 40-week mark, with many individuals on the drug transitioning from severe baseline impairment to mild or no impact.

Additionally, the investigators noted improvements across key functional and emotional domains, including mobility, pain, and mood. Kimball and colleagues also found up to 43% of subjects reported clinically meaningful reductions in their level of pain, and roughly two-thirds achieved meaningful improvements in Dermatology Life Quality Index (DLQI) scores.

The safety profile of this medication was shown to be consistent with earlier findings, with Kimball et al finding no new safety signals over 40 weeks of treatment.

Kimball’s institution received grants from Abbvie, Admirx, Anapyts Bio, Aristea, Bristol Myers Squibb, Chemocentryx, Eli Lilly, Incyte, Janssen, MoonLake, Novartis, Pfizer, Prometheus, UCB; Sonoma Bio. Kimball received consulting fees from Abbvie, Alumis, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Janssen, Moonlake Novartis, Pfizer, Priovant, Sonoma Bio, Sanofi, UCB; Target RWE, Ventyx; and serves on the board of directors of Almirall.

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting. MoonLake. March 28, 2026. Accessed March 30, 2026. 

https://www.globenewswire.com/news-release/2026/03/28/3264203/0/en/MoonLake-announces-Week-40-Results-from-its-Phase-3-Clinical-Trials-of-Sonelokimab-in-Hidradenitis-Suppurativa-at-the-2026-AAD-Annual-Meeting.html

Kimball A. Sonelokimab in moderate-to-severe HS: long-term results through week 40 of two phase 3 trials. Presented at: 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, CO.

This interview highlights phase 3 findings on sonelokimab for individuals with hidradenitis suppurativa (HS).

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Pranav Garimella, MBBS, MPH, is chief medical officer of the American Kidney Fund.

Garimella discusses the history, clinical impact, and rationale for removing race-based GFR from clinical decision-making.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

How Rewriting Race-Based GFR Equations Changed Kidney Transplant Access, With Pranav Garimella, MBBS, MPH

Michael E. Thase, MD, of the University of Pennsylvania

Inhaled GH001 achieved 57.5% remission by day 8 in TRD with a large effect size vs placebo; Thase discusses interpretation, unblinding, and phase 3 implications.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Single-Day GH001 Produces Rapid Remission in TRD, With Michael E. Thase, MD

Podcasts

David Cherney, MD, PhD, discusses REMODEL trial insights into how semaglutide reduces albuminuria and impacts kidney fat and fibrosis pathways.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Kidney Compass: Navigating Clinical Trials

Hosted by Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, Kidney Compass: Navigating Clinical Trials is a regular podcast exploring and breaking down the latest updates and nuances of clinical trials in nephrology. By listening to Kidney Compass, you'll get the guidance you need to navigate the changing landscape of clinical trials across the spectrum of kidney disease. 

Kidney Compass: REMODEL Trial Provides Mechanistic Rationale for Semaglutide in CKD

Martin de Borst, MD, PhD, discusses IV iron use in transplant recipients through an RCT focused on exercise capacity, function, and quality of life.

Kidney Compass: IV Iron and Functional Outcomes in Kidney Transplant Recipients

Katherine Tuttle, MD, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington.

REMODEL reveals how semaglutide protects kidneys, showing reduced inflammation, improved vascular health, and evidence of structural repair in diabetic CKD.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

From FLOW to REMODEL: Understanding Semaglutide in CKD, With Katherine Tuttle, MD

This interview highlights new 12-month, real-world data on tralokinumab and its long-term efficacy in patients with skin of color who live with atopic dermatitis.

TRACE: Tralokinumab Data for Atopic Dermatitis in Skin of Color, With April Armstrong, MD, MPH

Thierry Passeron, MD, PhD, is a professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

Patients with non-segmental vitiligo (NSV) on upadacitinib versus placebo showed continuous improvement over 48 weeks with no plateau.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Upadacitinib Safe, Effective Over 48 Weeks for Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

As patients increasingly turn to ChatGPT for mental health support, psychiatrists and ethicists weigh the clinical risks, ethical concerns, and what clinicians should do next.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Your Patient's New Therapist Is an AI. Now What?

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

New information from the phase 3 SCOUT-HCM trial indicate the benefits of mavacamten may extend to adolescents as well as adults. 

Cardiomyopathy

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Mavacamten Shows Benefit for Pediatric Patients in SCOUT-HCM Trial

Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.

Latest News

ONWARD: Oral Envudeucitinib Demonstrates High PASI Responses in Phase 3, With Andrew Blauvelt, MD

RADIANT-AD: Rademikibart Effective Over 52 Weeks in Atopic Dermatitis, With Cheng Zhou, MD

REMIX: Early CSU Symptom Improvement Observed with Remibrutinib Therapy

AI-Enhanced ECGs Detect Early COPD, With Monica Kraft, MD

VELA: Phase 3 Data Suggest Sonelokimab Effective for HS, With Alexa Kimball, MD, MPH